Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
CEFOBID vs CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
1-2 g IV every 6-8 hours. Maximum 12 g/day.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic